Tag Archives: Brexafemme

Some newer azoles are still in development, but most only target candidiasis.  Many years ago we saw development of nikkomycin (Nik Z), a drug mainly for coccidioidomycosis (Valley Fever).  It has no appreciable activity against candida or aspergillus.  Then there is ibrexafungerp, a promising new agent against C. albicans and Continue reading The Antifungal Landscape – 1→